Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
作者： D. Przepiorka , N. A. Kernan , C. Ippoliti , E. B. Papadopoulos , S. Giralt
DOI: 10.1182/BLOOD.V95.1.83.001K18_83_89
关键词:
摘要: Daclizumab, a humanized monoclonal IgG1 directed against the chain of interleukin-2 receptor (IL-2R), is competitive inhibitor IL-2 on activated lymphocytes. To test hypothesis that specific inhibition lymphocytes in patients with ongoing acute graft-versus-host disease (GVHD) might ameliorate process, we treated 43 advanced or steroid-refractory GVHD daclizumab. The first cohort 24 was daclizumab 1 mg/kg days 1, 8, 15, 22, and 29. On day 43, complete response (CR) rate 29% (95% confidence interval [CI], 13%-51%). Survival 120 CI, A second 19 4, 22. For these patients, CR 47% 24%-71%), survival 53% 29%-76%). There were no infusion-related reactions serious side effects related to Following treatment, there reduction serum concentrations soluble IL-2R peripheral blood CD3 + 25+ lymphocytes, but changes not predictive response. Daclizumab has substantial activity for treatment GVHD, regimen evaluated recommended controlled study. (Blood, 2000; 95:83-89)
ashpublications.org
bloodjournal.org
elsevier.com参考文章(52)
Baurmann H, Huhn D, Schmidt Ca, Henze G, Schmid Hj, Schwerdtfeger R, Siegert W, Josimovic-Alasevic O, Musch R, Hartmann R, Soluble interleukin 2 receptors in patients after bone marrow transplantation. Bone Marrow Transplantation. ,vol. 6, pp. 97- 101 ,(1990)
MM Zutter, PJ Martin, GE Sale, HM Shulman, L Fisher, ED Thomas, DM Durnam, Epstein-Barr virus lymphoproliferation after bone marrow transplantation Blood. ,vol. 72, pp. 520- 529 ,(1988) , 10.1182/BLOOD.V72.2.520.520
Flavio Vincenti, Robert Kirkman, Susan Light, Ginny Bumgardner, Mark Pescovitz, Philip Halloran, John Neylan, Alan Wilkinson, Henrik Ekberg, Robert Gaston, Lars Backman, James Burdick, Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation New England Journal of Medicine. ,vol. 338, pp. 161- 165 ,(1998) , 10.1056/NEJM199801153380304
G. L. Phillips, D. E. Reece, R. J. G. Cuthbert, H.-G. Klingemann, S. H. Nantel, J. D. Shepherd, M. J. Barnett, Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplantation. ,vol. 10, pp. 451- 455 ,(1992)
H D Volk, S Brocke, H Osawa, T Diamantstein, Effects of in-vivo administration of a monoclonal antibody specific for the interleukin-2 receptor on the acute graft-versus-host reaction in mice Clinical and Experimental Immunology. ,vol. 66, pp. 126- 131 ,(1986)
Przepiorka D, Weisdorf D, Hows J, Beatty P, Martin P, Klingemann Hg, Thomas Ed, 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantation. ,vol. 15, pp. 825- 828 ,(1995)
M S Kriete, F G Roberge, C C Chan, Y Guex-Crosier, J Raber, J Hakimi, R S Pilson, J Benichou, J A Kerwin, T A Waldmann, Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. Journal of Immunology. ,vol. 158, pp. 452- 458 ,(1997)
A Biuckians, F W Alt, L Van Parijs, A K Abbas, A Ibragimov, D M Willerford, Functional responses and apoptosis of CD25 (IL-2R alpha)-deficient T cells expressing a transgenic antigen receptor. Journal of Immunology. ,vol. 158, pp. 3738- 3745 ,(1997)
T A Waldmann, W J Leonard, R J Robb, W C Greene, J M Depper, Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. Journal of Immunology. ,vol. 131, pp. 690- 696 ,(1983)
PJ Martin, G Schoch, L Fisher, V Byers, FR Appelbaum, GB McDonald, R Storb, JA Hansen, A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment Blood. ,vol. 77, pp. 1821- 1828 ,(1990) , 10.1182/BLOOD.V77.8.1821.1821